Clinical Trial: Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation

U.S., Jan. 22 -- ClinicalTrials.gov registry received information related to the study (NCT07354477) titled 'Single-site Pilot Study Evaluating the Effect of QLS-111 Ophthalmic Solution on Posterior Perfusion and Vessel Dilation' on Dec. 22, 2025.

Brief Summary: Pilot, single-site, prospective study of QLS-111 0.015 % in subjects with NPDR, OAG or NTG

Study Start Date: Jan. 30

Study Type: INTERVENTIONAL

Condition: Non-proliferative Diabetic Retinopathy (NPDR) Open-angle Glaucoma (OAG) Normal Tension Glaucoma (NTG)

Intervention: DRUG: QLS-111 Ophthalmic Solution (0.015%)

QLS-111 (0.015%) administered BID for 7 days OU.

DRUG: QLS-111 Ophthalmic Solution (0.075%)

QLS-111 (0.075%) administered BID for 7 days OU. Follows the 7 days whe...